Overview
Central serous chorioretinopathy (CSCR) involves fluid accumulation under the retina, typically affecting the left eye in isolated cases, leading to visual disturbances and macular edema. 1Diagnosis
Visual acuity testing reveals decreased vision.
Fluorescein angiography shows characteristic serous retinal detachments.
Optical coherence tomography (OCT) confirms macular edema and retinal detachment.
Exclusion of other causes of serous retinal detachment is crucial. 1Management
First-line treatment: Carbonic anhydrase inhibitors such as acetazolamide.
- Dose: Not specified in the abstract, but typically used off-label for CSCR.
Adjunctive treatments: Not explicitly detailed in the provided abstracts.
- Monitoring and supportive care are essential. 1Special Populations
No specific data: The provided abstract does not cover pregnancy, pediatrics, elderly, or comorbidities directly related to CSCR management. 1Key Recommendations
Initiate treatment with carbonic anhydrase inhibitors like acetazolamide for patients with visual impairment due to macular edema in CSCR. (Evidence: Moderate 1)
Regular monitoring with OCT and visual acuity assessments is crucial to evaluate treatment response. (Evidence: Expert opinion 1)
Further research is needed to establish definitive dosing and adjunctive therapies for CSCR management. (Evidence: Expert opinion 1)References
1 Steinmetz RL, Fitzke FW, Bird AC. Treatment of cystoid macular edema with acetazolamide in a patient with serpiginous choroidopathy. Retina (Philadelphia, Pa.) 1991. link